DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  This decline in R&D is attributed to scientific challenges associated with identifying new antibiotic targets and the relatively low return on investment compared to other therapeutic areas like oncology or rare diseases.  million deaths associated with it.

Pharmaceutical Companies 71

Pharmaceutical Companies Government Pharmaceuticals DNA 71

The Pharma Data

APRIL 22, 2023

Since 1997, WHO and UNICEF have jointly collected information on immunization programmes and vaccine-preventable diseases. Data is gathered annually and used to support important global and regional monitoring and planning functions, as well as track progress towards global and regional indicators.

Vaccine 40

Vaccine Disease 40

PerkinElmer

JANUARY 25, 2023

Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more.

Science 52

Science Laboratories Immune Response Disease 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. MenAfriVac is a meningococcal vaccine that remains active, without refrigeration, for up to four days and has significantly boosted vaccine coverage in parts of sub-Saharan Africa. We further estimate that supplying just the U.S.

Engineering 84

Engineering Vaccine Production RNA 84

NIH Director's Blog: Drug Development

MAY 15, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH As a volunteer physician in a small hospital in Nigeria 30 years ago, I was bitten by lots of mosquitoes and soon came down with headache, chills, fever, and muscle aches. In 2016 alone, an estimated 216 million people were treated for the disease.

Drug Development 52

Drug Development Drugs Disease Treatment 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. Rare Disease. Others Rare Disease. Total Rare Disease. Polio/Pertussis/Hib vaccines (incl.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

MAY 4, 2021

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

OCTOBER 25, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s donation to appreciatively impacting health, societal and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals.

Vaccine 52

Vaccine Hospitals Disease Treatment 52

The Pharma Data

MARCH 11, 2021

In the pharmaceutical sector, new technologies could help us not only to treat but probably cure or even prevent diseases,” Baumann said. Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

JULY 11, 2021

Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.

Immune Response 52

Immune Response Disease Vaccine Licensing 52

The Pharma Data

DECEMBER 18, 2020

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors. billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC.

Vaccine 52

Vaccine Government International Virus 52

The Pharma Data

FEBRUARY 8, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

SEPTEMBER 15, 2020

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

Codon

MARCH 3, 2024

More than 100 billion animals are killed for meat and other animal-derived products every year and there is a staggering number of wild animals that face disease, starvation, and predation in natural and urban environments. Link Making Pan-Vaccines Current vaccines typically offer narrow protection against pathogens, such as influenza.

DNA 79

DNA Engineering Vaccine Virus 79

The Pharma Data

NOVEMBER 12, 2020

Highlighted in a publication by the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC) , measles cases worldwide increased to 869,770 in 2019, the highest number reported since 1996 with increases in all WHO regions. MCV2 coverage has been steadily increasing but is only now at 71 percent.

Vaccine 52

Vaccine Virus Disease 52